SHetA2 for Treatment of Cervical Intraepithelial Neoplasia

By
SHetA2 therapy is an investigational oral small-molecule drug designed to treat HPV-related precancerous cervical lesions and advanced solid tumors by targeting heat shock proteins without high toxicity. It was co-developed by the Indian Council of Medical Research (ICMR) National Institute of Cancer Prevention and Research and the University of Oklahoma. 

About the Technology: SHetA2 selectively targets HPV-driven oncogenesis, with the potency to kill cancer cells while sparing normal cells. It targets mortalin, Hsc70, and Grp78 to disrupt HSP70/E7 complexes, reduce p16 expression, and inhibit tumor growth. SHetA2 has shown strong safety, tolerability, and improved bioavailability in preclinical and Phase 1 studies. Delivered orally or as a vaginal suppository, it offers a cost-effective, non-invasive, take-home therapy, well-suited for global use, including LMICs.

Need and utility of the Technology from Public health perspective: SHetA2 inhibits HPV induced tumor growth and shows promising results with low toxicity, in in vitro, preclinical, and ongoing Human Phase-I trial in the US, to support strong relevance for global cervical cancer elimination, especially in LMICs.

Validation Status and Study Outcome: 
• Inhouse Validation –Complete 
• Efficacy Outcome: SHetA2 suppresses cervical cancer growth by inhibiting HR-HPV E6/E7 oncoproteins through disruption of HSP70 interactions.

Market Potential: SHetA2 is a first-in-class, non-destructive therapy for Cervical pre-cancer and cancer lesions are suppressed by inhibiting abnormal cell growth. Unlike current ablative treatments with side-effect risks, SHetA2 aims to prevent cancer progression with no toxicity observed. 

Comments

Post a Comment

Popular posts from this blog

Rural Local Bodies in Kerala Receive Over ₹260 Crores as First Instalment of XV Finance Commission Grants

By
The Union Government has released ₹260.20 crores to Rural Local Bodies in Kerala as XV Finance Commission grants for the Financial Year 2025- 26. The amount represents the first instalment of Untied Grants and covers all 14 District Panchayats, 152 Block Panchayats and 9,414 Gram Panchayats in the State. The Ministry of Panchayati Raj and the Ministry of Jal Shakti (Department of Drinking Water and Sanitation) recommend the release of XV FC Grants for RLBs/PRIs, which is subsequently released by the Ministry of Finance in two installments during a financial year. Untied Grants are meant to be utilized by Rural Local Bodies/PRIs for location-specific felt needs under the 29 subjects listed in the Eleventh Schedule of the Constitution, except for salaries and other establishment expenditures. Tied Grants, on the other hand, are earmarked for basic services relating to (a) sanitation and maintenance of ODF status including management and treatment of household waste, human excreta and fec...
Read more

ISRO developing semi-cryogenic engine working on LOX Kerosene propellant

By
ISRO is developing a 2000 kN thrust semi-cryogenic engine working on an LOX Kerosene propellant combination for enhancing the payload capability of LVM3 and for future launch vehicles. Liquid Propulsion Systems Centre (LPSC) is the lead centre for the development of semi-cryogenic propulsion systems with the support of other launch vehicle centres of ISRO. The assembly and testing of the propulsion modules were done at the ISRO propulsion complex (IPRC), Mahendragiri. As part of the engine development, a pre-burner ignition test article, which is a full complement of the engine power head system excluding the turbopumps is realized. The first ignition trial was conducted successfully on May 2, 2024, at semi cryo integrated engine test facility (SIET) at IPRC, Mahendragiri, which was dedicated to the nation recently by the honorable Prime Minister of India. Smooth and sustained ignition of the preburner is demonstrated which is vital for the starting of the semi-cryogenic engine. Semi-c...
Read more